<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964169</url>
  </required_header>
  <id_info>
    <org_study_id>10/08-16</org_study_id>
    <nct_id>NCT02964169</nct_id>
  </id_info>
  <brief_title>Family Planning and HIV in Postpartum Women in Mbarara</brief_title>
  <official_title>Family Planning Support and Its Impact on Pregnancy Desires and Contraceptive Use Among Recently Postpartum HIV Positive Women Delivering at Mbarara Regional Referral Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mbarara University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NIH Office of AIDS Research (OAR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mbarara University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supporting HIV positive women to delay or prevent an unwanted pregnancy may improve women's
      health through family planning choices, regular health reviews, and support. A cohort study
      that was done in Mbarara amongst HIV-infected women documented 50% of the enrolled women
      having no desire for a (another) child during the 4 years since ART initiation, 51% had a
      serodiscordant partner, with only 45% using effective contraceptive method. Key predictors of
      contraceptive use were family planning goals within the DYAD. One of the key predictors of
      effective contraceptive use was male partner involvement and CD4 count. The WHO recommends
      dual contraception (use of condoms and a hormonal or permanent method) to prevent both HIV
      transmission and unwanted pregnancies (WHO,2014).This prospective intervention study aims at
      providing information on whether continuous family planning accessibility and support has a
      measurable impact on pregnancy intentions and contraceptive usage among postpartum HIV
      positive mothers delivering at MRRH, SW Uganda.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV status and availability of ART have been found to widely influence the desirability and
      expectations to have children among childbearing women living with HIV (Nieves et al., 2015;
      Kaida et al., 2011). Up to 85% of the pregnancies within 3 years following ART are often
      unwanted, often leading to illegal abortions and maternal deaths (Desgrees-Du-Lou et al.,
      2002).

      Uganda's HIV epidemic has declined over time to about a sero prevalence of 7.2% and this
      decline has been attributed in part to improved prevention behavior like condom use,
      reduction in multiple concurrent partnerships and other strategies to prevent unwanted
      pregnancies. Specifically, HIV prevalence is estimated at 7% among women attending antenatal
      clinics in Uganda (UN, 2010). Whereas ART availability has improved general health outcomes
      through viral load suppression and immune reconstitution, there is still a high unmet need
      for family planning among HIV positive women in Uganda (Snow et al., 2011), where modern
      contraceptive prevalence is at 33% in the general population despite the widespread
      promotional messages across the country. This continues to expose HIV positive women to
      increased risks of unwanted/unplanned pregnancies, perinatal HIV transmission, pregnancy
      complications, and increased economic burden of care for self and others among others.

      The high average fertility rate of 5.9 children per woman in Uganda may further complicate
      the immunity and wellbeing of the already burdened HIV positive women and their families even
      amongst those already accessing HIV care (Muyindike et al., 2012; Homsy et al., 2009).

      Supporting HIV positive women to delay or prevent an unwanted pregnancy may improve women's
      health through family planning choices, regular health reviews, and support. A cohort study
      that was done in Mbarara amongst HIV-infected women documented 50% of the enrolled women
      having no desire for a (another) child during the 4 years since ART initiation, 51% had a
      serodiscordant partner, with only 45% using effective contraceptive method. Key predictors of
      contraceptive use were family planning goals within the DYAD. One of the key predictors of
      effective contraceptive use was male partner involvement and CD4 count. The WHO recommends
      dual contraception (use of condoms and a hormonal or permanent method) to prevent both HIV
      transmission and unwanted pregnancies (WHO,2014).This prospective intervention study aims at
      providing information on whether continuous family planning accessibility and support has a
      measurable impact on pregnancy intentions and contraceptive usage among postpartum HIV
      positive mothers delivering at MRRH, SW Uganda.

      General objective To test the effect of a family planning availability and support
      intervention on pregnancy intentions and use of effective contraception among recently
      postpartum women living with HIV who delivered at MRRH.

      Specific objectives

        1. To assess the influence of the intervention on pregnancy intentions among recently
           postpartum HIV positive mothers delivering at MRRH, SW Uganda one year after the
           intervention.

        2. To assess the impact of the intervention (voucher) on contraceptive uptake among
           recently postpartum HIV positive mothers delivering at MRRH, SW Uganda

        3. To assess the influences of the intervention (SMS +Partner involvement) on contraceptive
           uptake among recently postpartum HIV positive mothers delivering at MRRH, SW Uganda

        4. To identify factors that influence pregnancy intentions and contraceptive use

        5. To assess the influence of the intervention on the incidence of unintended pregnancy
           among recently postpartum HIV positive mothers delivering at MRRH, SW Uganda

        6. To explore decision making challenges and perceptions of family planning among HIV
           positive women.

        7. To assess the role of sexual partners on pregnancy intentions and effective
           contraceptive use

      Methods This will be a prospective randomized controlled trial of 2 arms. I. The
      investigators intend to enroll a total of 320 HIV positive women delivering at MRRH. The
      participants will be equally randomized into the intervention arm (Family planning support)
      and control group (no family planning support, except the routine counseling following
      discharge). These women will be followed for 1 year. Their male partners will also
      voluntarily choose to participate in the study or not. Eligibility will also require access
      to a mobile phone.

      II. Intervention group. Following delivery, the participants will be given a voucher to
      freely access any of the five family planning options of their choice. A voucher will also be
      given to the spouse/sexual partner due to its identified effect on family planning
      utilization (Ashraf et al., 2014). Although family planning is already free, there are
      usually stock outs. The voucher will therefore be an incentive to access the family planning
      timely (maximum of 1 hour waiting time) and continuously from the study in case of stock
      outs. These include; condoms (40 condoms), injectables, contraceptive pills, copper IUD and
      contraceptive implants. The women will be contacted at 6 weeks postpartum for initiation of
      family planning by a study nurse well trained in specialized family planning care and support
      for HIV positive women if they have not done so yet. The choice of family planning will be
      entirely up to the participants. For those women who select oral contraceptive pills, women
      will be sent daily [adherence support] reminders for the first 4 months, then weekly
      reminders (via SMS) for the next 4 month and then monthly for the next 4 months. This level
      of SMS support has been found to have a positive impact on adherence (Haberer et al., 2016).
      Sexual partners/regular spouses of women in intervention arm will also receive these
      reminders weekly [but not daily or monthly] throughout the study. The reminders will also be
      sent monthly if one chooses an injectable contraception [consider whether it's the 2-month or
      3-month injectable] for the 12 study months. Daily reminders will also be sent for women who
      choose male or female condoms. Routine reviews on family planning will be done for women in
      the intervention arm alongside their routine visits at the HIV clinic or post-natal PMTCT
      visits. Interviews with study participants will be done at baseline, 6 and 12 months
      postpartum. The spouses/ sexual partners will be contacted, enrolled and interviewed at
      baseline, 6 months and at 1 year.

      III. Control group: These will be counseled on family planning at discharge and enrolled.
      They will be interviewed at baseline, 6 months and 1 year. Data on reproductive history,
      HIV/AIDS experience, socio-sexual relationships, fertility aspirations, use and knowledge of
      family planning, decision making, and perceptions on Family planning, alcohol use, food
      security, education, socio-economic, side effects or undesirable effects, economic and social
      support will be documented.

      Natural family planning methods like lactation amenorrhea, withdrawal methods and others have
      been presented with mixed literature, painting a grim picture on their effectiveness as
      standalone contraceptive methods especially among HIV positive women. All women are advised
      to exclusively breast feed for 6 months while on ART (MoH, 2015). Because hormonal
      contraception inclusive of estrogen interferes with breast milk production among lactating
      mothers, progestin-only methods will be recommended to the women.

      IV. Randomization:

      Consecutive numbers ranging from 001 to 320 will be computer generated to indicate the 2 main
      groups into which mothers can be randomly assigned and enrolled. These consecutive numbers
      will be labeled on top of the opaque envelopes. To be eligible, mothers must be HIV positive,
      have had a delivery within the last 48 hours, above 18 years of age, anticipating to begin
      family planning at 6 weeks postpartum, must be mentally stable and qualify for any family
      planning method available. Once eligibility of a mother is confirmed, they will be invited to
      participate in the study.

      The aim of the study and details of the procedures to be involved in the trial, potential
      side effects and therapeutic benefits will be explained before randomization occurs. Once the
      mothers consent to participate in the study, a study number will be allocated by the nurse
      research assistant (who will be recruited to work on the ward/post natal clinic for this
      study) by taking the next in a series of similar opaque envelopes provided to conceal
      allocation of groups. These opaque envelopes will be labeled with computer-generated list of
      numbers with group allocation (either Intervention group or Control Group) of the mothers
      randomized in blocks of 20. Nurse research assistants will be blinded to the group allocation
      until eligibility and study participation is confirmed. The research assistants will also be
      blinded to hypothesis of the study.

      A blood sample will be drawn at baseline to confirm the HIV status and or do a CD4 cell count
      in case it is unknown at the time of enrollment. This will be done to support women enroll
      for the recommended Option B+ in case the women are not yet lifelong ART].

      A different study nurse will be enrolled and trained to specifically collect data from
      participants. The socio-demographic data and obstetric characteristics will be documented.
      Other documented potential covariates of contraceptive use like participant age, primary
      partner's age, primary partner's HIV status, personal and partner fertility desires, number
      of children, most recent CD4 cell count, Efavirenz-containing ART Regimen (due to its
      association in decreasing levels of hormonal contraception thus recommending dual methods and
      its teratogenicity concerns- although these concerns have been found to be exaggerated),
      socio-economic status, body mass index, education level, time on ART . Prior contraceptive
      use experiences, fertility desire/ pregnancy intentions or aspiration will be measured using
      the CDC pregnancy Risk Assessment Monitoring System Instrument (Ahluwalia et al., 1999)

      Effective contraception use will be defined as consistent use [both self report and
      observational chart review from study nurse at the family planning clinic] of a family
      planning method (including consistent condom use) , including dual contraception (use of
      condoms and another contraceptive method-hormonal or permanent) for HIV-sero discordant
      couples/partners (for participants who know partner's status). A primary partner will be
      defined either as a regular spouse, who is also a regular sexual partner or the most recent
      sexual partner if no main partner is named. These sexual partners will also be enrolled and
      interviewed at baseline and at 1 year. In case a consented mother ends up with a serious
      adverse event, the time and indication will be documented and reported. In case a woman
      changes the contraceptive method, the reasons for the change will also be documented.

      Data Preparation All data will be cross checked for completeness before entry. Data will be
      coded and entered independently into the excel sheet and exported into STATA Version 12 for
      statistical analysis. For each variable, a reference category will be identified.

      Data Analysis Plan Data analysis will be by intention-to-treat (ITT) consisting of all
      mothers randomized and thus supposed to be treated (Lesaffre, 2008). Descriptive statistics
      will be used to describe key characteristics of study participants. Different variables will
      be explored for normal distribution. Continuous variables will be compared with binary
      outcomes of contraception effectiveness and pregnancy intentions using a t- test. Selected
      demographic, clinical, post-natal factors will be compared for differences and similarities
      in the three groups. Crude relative risks will be derived. Relative risks with 95% confidence
      Interval (two tailed) will be calculated and used to compare contraception effectiveness and
      pregnancy intentions in all groups. Factors associated with effective contraception use and
      pregnancy intentions will be explored using univariate analysis and for results whose p value
      â‰¤ 0.10, a multivariate analysis will be done to rule out confounding factors.

      Data Reporting The means will be presented with their standard deviations. Relative risks and
      odds ratios will be presented with their 95% confidence Intervals. Two-tailed statistical
      analysis will be used and statistical significance will be defined at level of p &lt; 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed consistent use of an effective contraceptive method at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnancy desire/aspirations among the HIV positive women</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>HIV and Family Planning</condition>
  <arm_group>
    <arm_group_label>Family Planning Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Family planning voucher and phone reminders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Family Planning Support</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Family Planning Support</intervention_name>
    <arm_group_label>Family Planning Support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mothers must be HIV positive

          -  Have had a delivery within the last 48 hours

          -  Above 18 years of age

          -  Anticipating to begin family planning at 6 weeks postpartum

          -  Must be mentally stable and qualify for any family planning methods available.

        Exclusion Criteria:

          -  Mothers who are HIV negative

          -  Less than 18 years of age

          -  Not anticipating to begin family planning at 6 weeks post partum

          -  Mentally unstable or dont qualify for any family planning methods available.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Esther C Atukunda, PhD</last_name>
    <phone>+256 782 949832</phone>
    <email>eatukunda@must.ac.ug</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mbarara Regional Referral Hospital</name>
      <address>
        <city>Mbarara</city>
        <zip>00256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Atukunda, PhD</last_name>
      <phone>+256 782949832</phone>
      <email>eatukunda@must.ac.ug</email>
    </contact>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

